Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00550134
Other study ID # 07-130
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 24, 2007
Est. completion date December 28, 2021

Study information

Verified date December 2021
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with cancer often complain that their "mind does not seem to be clear." This can be due to stress, depression, anxiety, or physical problems caused by cancer or the treatments used to control symptoms. There are many purposes for this study; one of them is to learn about the effects of cancer treatments on the brain, and another is to identify useful tools to detect these effects. The results of this study may stimulate new research comparing different treatments to the current treatment so the researchers may learn how to treat symptoms more effectively and improve patient quality of life. We would also like to learn more about the effects chemotherapy may have on DNA.


Description:

This is a prospective, longitudinal study to examine time-dependent neurocognitive changes in patients with breast cancer receiving adjuvant chemotherapy. This study will assess chemotherapy-induced cognitive dysfunction. The researchers will recruit patients with localized breast cancer undergoing adjuvant chemotherapy for the first time and will test the effects of chemotherapy on patients' cognitive function utilizing a standardized neuropsychological battery. Patients scheduled for chemotherapy will be given a battery of neuropsychological undergo MRI evaluation prior to beginning chemotherapy and one month following completion of treatment.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date December 28, 2021
Est. primary completion date December 28, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patient is 18 years of age but not older than 70years of age - Patient is female - Patient is able to understand English, through verbal and written communication - In the judgment of the investigator and/or the consenting professional patient is able to provide informed consent - Patient has a diagnosis of breast cancer (stage 0, I, II or IIIA-C), limited to localized disease, - Patient is chemotherapy naïve and is receiving chemotherapy or is scheduled to receive no chemotherapy as part of adjuvant treatment - Patient does not report history of prior breast or other cancer with the exception of non-melanoma skin cancer and/or participants who completed treatment for a previous cancer at least 5 years ago and have not undergone any chemotherapy. - Patient is able to undergo MRI scanning (verified with pre MRI Safety Screening form), - Patient can comfortably fit inside the MRI machine, verified by back to chest measurement no more than 10 inches or bust circumference of no more than 48 inches. Exclusion Criteria: - Patient has documented evidence of cognitive compromise (Blessed- Orientation Memory Cognition Test score > 11 - Patient has a history of neurological disorder with cognitive symptoms (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis) - Patient is Pregnant as confirmed by urine pregnancy test. Participants who are post menopausal or have had a hysterectomy do not need a pregnancy test - Patient is currently on daily medication for migraine or, insulin-dependent diabetes requiring administration by injection, - Patient has uncontrollable hypertension as per self report or as documented in the medical record - Patient has a reported fear of enclosed spaces (Claustrophobia) - Patient has any of the following items that preclude fMRI evaluation - Cardiac pacemaker, Joint replacements, Aneurysm clips, Transdermal patched, Aortic clips, Prosthesis, Intracranial bypass clips, Harrington rod , Coronary Artery bypass clips, Biostimulator, Renal Transplant Clips, Bone or joint pins, Other vascular clips or filters, Tissue expander ,Implanted neurostimulators, Metal mesh, Artificial heart valve, Stents, Insulin pump, Wire structures, Electrodes, Shrapnel/bullets, Hearing Aids implant, Implanted electrical devices, IUD, Metal in eyes, Shunts, Ocular Implants, Hair extensions, Hair implants, Tattoos above the waist, Any possible metal in body - Patient has dentures, body jewelry or wig that they are unable to remove - History of head injury with evidence of brain injury or loss of consciousness for > 60 minutes or cognitive sequelae - Untreated or current episode of depression (answering positively to either of the two screening questions from the PHQ-9 (Kroenke, et al., 2001) - Self-reported sleep disorders that could influence cognitive functioning including sleep apnea and and narcolepsy - History of Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia disorder (DSM-IV) or substance use disorders (self reported and/or stated in medical record) - History of schizophrenia, bipolar disorder or substance use disorders - Patient is unwilling to undergo fMRI component if selected - Patient has undergone previous chemotherapy treatment Healthy Control Inclusion Criteria: - Participant is 18 years of age but not older than 70 years of age, - Participant is female - Participant is able to understand English, through verbal and written communication - In the judgment of the investigator and/or the consenting professional participant is able to provide informed consent - Patient is able to undergo MRI scanning (verified with pre MRI Safety Screening form) - Patient can comfortably fit inside the MRI machine, verified by back to chest measurement no more than 10 inches or bust circumference of no more than 48 inches. Healthy Control Exclusion Criteria: -Participant has Documented evidence of severe cognitive compromise (Blessed- Orientation Memory Cognition Test score > 11 - Participant has a history of neurological disorder with cognitive symptoms (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis). - Participant is pregnant as indicated by urine pregnancy test, - As per self report participant is currently on daily medication for migraine, or , insulin dependent diabetes requiring administration by injection, - As per self report participant has uncontrollable hypertension, - As per self report, participant has a reported fear of enclosed spaces (Claustrophobia) - As per self report, participant has any of the following items that preclude fMRI evaluation Cardiac pacemaker, Joint replacements, Aneurysm clips, Transdermal patched, Aortic clips Prosthesis, Intracranial bypass clips, Harrington rod , Coronary Artery bypass clips, Biostimulator, Renal Transplant Clips, Bone or joint pins, Other vascular clips or filters, Tissue expander ,Implanted neurostimulators, Metal mesh, Artificial heart valve, Stents, Insulin pump, Wire structures, Electrodes, Shrapnel/bullets, Hearing Aids implant, Implanted electrical devices, IUD, Metal in eyes, Shunts, Ocular Implants, Hair extensions, Hair implants, Tattoos above the waist, Any possible metal in body - As per self report, participant has dentures, body jewelry or wig that they are unable to remove - As per self report, participant has a history of head injury with evidence of brain injury or loss of consciousness for > 60 minutes or cognitive sequelae - As per self report, participant has untreated or current episode of depression (answering positively to either of the two screening questions from the PHQ-9 (Kroenke, et al., 2001) - As per self report, participant has sleep disorders that could influence cognitive functioning including sleep apnea and narcolepsy, - As per self report, participant has history of Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia disorder (DSM-IV) or substance use disorders - As per self report, participant has undergone previous chemotherapy treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Questionnaires, MRI, Comet assay and Cell senescence
Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
Questionnaires, MRI, Comet assay and Cell senescence
Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
Questionnaires, MRI, Comet assay and Cell senescence
Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence

Locations

Country Name City State
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (5)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Biomedical Engineering Newark College of Engineering New Jersey Institute of Technology, Brigham and Women's Hospital, The City College of New York, Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate changes in cognitive performance pre- to post-chemotherapy in breast cancer patients. approximately 4 to 6 months from baseline, depending on chemotherapy regimen
Secondary To evaluate associations between changes in frontal cortex and hippocampal volumes and activation patterns and changes in neuropsychological test performance. 4 to 6 months
Secondary To evaluate the relationship between change in level of oxidative DNA damage markers of cell senescence (Telomere attrition) and changes in volume and activation patterns in prefrontal cortex and hippocampus. 4 to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2